Endometrial cancer recurrence carries a poor prognosis. The rising incidence of endometrial cancer calls for improvements in treatment of advanced and recurrent diseases. Efforts have been made to molecularly characterize endometrial cancer with the goal of improving therapies. The study presented here describes the utilization of molecular features of endometrial cancer tumors that are likely to recur, along with clinical characteristics utilized together to predict recurrence. This work further studies recurrent endometrial cancers to group them into "clusters" based on the tumor's molecular makeups with the ultimate aim to focus therapy on the molecular pathways potentially leading to recurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/GRF.0000000000000498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
Oncogene
January 2025
Department of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 201204, China.
The Role of hCG Expression in Endometrial Cancer Prognosis.
Int J Gynecol Pathol
January 2025
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Muğla Sitki Koçman University, Muğla, Turkey.
This study aims to investigate the expression pattern of human chorionic gonadotropin (hCG) in the tissue of endometrioid type endometrial cancer (EEC) using immunohistochemistry, and also to investigate the effect of hCG expression pattern on prognosis and survival in EEC. We evaluated patients who were operated between 2010 and 2020 in the obstetrics and gynecology clinic of our center due to EEC. In total, 194 women were determined to be in either the hCG-negative group (n=137) or the hCG-positive group (n=57).
View Article and Find Full Text PDFSearch for Healthcare and Breast/Gynecological Cancer Prevention Among Brazilian Lesbian Cisgender Women.
Cancer Invest
January 2025
Psychology Department, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto-SP, Brazil.
Although breast, cervical, endometrial, and ovarian cancers account for more than 43% of new cases in 2023 in Brazilian women, no national studies were found on the incidence, risk factors, and prevention of breast and gynecological neoplasms in lesbian women, causing the health needs of non-heterosexual women to go unnoticed by professionals. This study aims to identify and analyze the search for healthcare related to the prevention of breast/gynecological cancer among Brazilian lesbian cisgender women who have not had the disease. Seven lesbian women participated in this qualitative study.
View Article and Find Full Text PDFModeling dosimetric benefits from daily adaptive RT for gynecological cancer patients with and without knowledge-based dose prediction.
J Appl Clin Med Phys
January 2025
Department of Radiation Medicine and Applied Sciences, UC San Diego Health, La Jolla, California, USA.
Purpose: Daily online adaptive radiotherapy (ART) improves dose metrics for gynecological cancer patients, but the on-treatment process is resource-intensive requiring longer appointments and additional time from the entire adaptive team. To optimize resource allocation, we propose a model to identify high-priority patients.
Methods: For 49 retrospective cervical and endometrial cancer patients, we calculated two initial plans: the treated standard-of-care (Initial) and a reduced margin initial plan (Initial) for adapting with the Ethos treatment planning system.
Surgical management of endometrial cancer in patient with musculocontractural Ehlers-Danlos Syndrome harboring pathogenic variants in CHST14 (mcEDS-CHST14): A case report.
Gynecol Oncol Rep
February 2025
Department of Obstetrics and Gynecology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan.
Introduction: Musculocontractural Ehlers-Danlos syndrome (mcEDS) is a rare autosomal recessive connective tissue disorder caused by systemic depletion of dermatan sulfate. Symptoms characteristic of mcEDS include multiple contractures, fragile skin with subcutaneous bleeding, and hypermobile joints, which suggest difficulty in perioperative management. However, safe surgical techniques and perioperative management of this disorder remain unknown because of its rarity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!